Executive Summary
Optimum Imaging Technologies and Olympus have reached a settlement-in-principle in the district court case tied to IPR2024-01373, requesting a 45‑day stay to finalize dismissal. The agreement ends the PTAB challenge to patent 7,612,805.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Nikon Corporation et al. vs Optimum Imaging Technologies LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Askeladden L.L.C.vsIntercurrency Software LLC
Askeladden L.L.C. successfully petitioned to institute IPR proceedings against Intercurrency Software LLC's '863 patent, challenging all twelve claims based on obviousness (103). The Board found that the Petitioner demonstrated a reasonable likelihood of prevailing with respect to at least one claim challenged in the Petition.
Google LLCvsDialect LLC
Google LLC's IPR challenge against Dialect LLC's patent was denied by the PTAB, finding insufficient evidence of obviousness over prior art (Coffman, Kennewick, Ross). The Board agreed with the Patent Owner that the prior art disclosures were too high-level to support the combination claimed.
Ubiquiti Inc.vsIntellectual Ventures I
Ubiquiti Inc.'s IPR challenge against Intellectual Ventures I LLC was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of success, particularly regarding the key SIFS limitation in wireless communication claims.
TikTok Inc. et al.vsCellspin Soft, Inc.
TikTok Inc.'s challenge to Cellspin Soft's patent was instituted by the PTAB, finding a reasonable likelihood that at least one challenged claim is unpatentable. The Board focused on obviousness (35 U.S.C. § 103) over prior art references including Hiroishi, Kahn, and Bluetooth specifications. This decision sets up trial proceedings to determine if the combination of existing technologies renders the patent claims invalid.
Apotex Inc.vsIpsen Biopharm Ltd. et al.
The PTAB granted institution for the IPR involving Apotex Inc. and Ipsen Biopharm Ltd., allowing the merits of the challenge to proceed.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.